Pasritamig

Pasritamig (JNJ-78278343; KLCB-245) is a bispecific T-cell engager ( BiTE ) that targets the complex of human kallikrein KLK2 and CD3 receptor. Pasritamig redirects the cytotoxicity of T cells to KLK2 -expressing tumor cells and induces T cell-mediated lysis of KLK2 -expressing prostate cancer cells. Administered via subcutaneous injection, subcutaneous infusion or intravenous infusion, Pasritamig exhibits antitumor activity against metastatic castration-resistant prostate cancer. Pasritamig has a safety profile with an extremely low incidence of cytokine release syndrome and can be safely administered in an outpatient setting. Pasritamig is applicable to the research of metastatic castration-resistant prostate cancer ^{[1] [2] [3] [4]}.

In Vivo, At subcutaneous injection doses of 0.5~2000 μg/mL and intravenous injection doses of 150~900 μg/mL, Pasritamig exhibits linear and non-linear (KLK2-mediated) elimination in an open two-compartment model, with a terminal half-life of 18.3 days, and its exposure increases in an approximately dose-proportional manner^[2].

References:
[1]. Stein MN, et al. Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. J Clin Oncol. 2025;43(22):2515-2526.
[2]. Cui J, et al. 298eP Preliminary results of a multicenter, open-label, randomized, phase II trial (ALTER-PA-001 trial) of anlotinib and benmelstobart in combination with AG versus AG as first-line treatment for metastatic pancreatic cancer[J]. Immuno-Oncology and Technology, 2025, 28.
[3]. Meng L, Yang Y, Mortazavi A, Zhang J. Emerging Immunotherapy Approaches for Treating Prostate Cancer. Int J Mol Sci. 2023 Sep 20;24(18):14347.
[4]. Wang X, et al. 305eP Camrelizumab combined with nab-paclitaxel as second-line therapy for advanced biliary tract cancer (BTC): A real-world study[J]. Immuno-Oncology and Technology, 2025, 28.